Almirall reports 12.7% revenue growth in H1 2025, driven by dermatology portfolio
BARCELONA: Almirall, S.A. (ALM), a global biopharmaceutical company specializing in medical dermatology, reported a 12.7% increase in net sales for the first half of 2025, reaching €560.5 million, up from €497.2 million in the same period last year. EBITDA rose…